Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)Peter Nash, Jacob Aelion, Juan J. Gómez‐Reino et al.|Annals of the Rheumatic Diseases|2018Cited by 88
OP0219 Early onset of efficacy with apremilast monotherapy in biologic-naÏve patients with active psoriatic arthritis: a phase 3b, randomized, controlled trialPeter Nash, Aelion Ja, Kamal Ohson et al.|Annals of the Rheumatic Diseases|2017Cited by 3
AB0943 Sustained improvements with up to 104 weeks of apremilast monotherapy in biologic-naÏve subjects with active psoriatic arthritis: results from a phase 3b, randomised, controlled trialPeter Nash, Jacob Aelion, Juan J. Gómez‐Reino et al.|Annals of the Rheumatic Diseases|2018Cited by 0